Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability
- 384 Downloads
The universal vaccination of children for influenza has recently been recommended in the UK and is being considered in other developed countries.
The aim of this study was to explore the potential costs and benefits of childhood influenza vaccination to gain a better understanding of the key drivers of cost-effectiveness.
As our case study we examined the cost-effectiveness of vaccination in Australian schoolchildren using an age-stratified Susceptible Exposed Infectious Recovered model.
The results of this study highlight the critical role that methodological choices play in determining the cost-effectiveness of influenza vaccination. These choices include decisions about the structure of the model (including/excluding herd immunity) and what costs and benefits to include in the analysis. In scenarios where herd protection was included we estimated that the program was likely to be cost-effective. The study also illustrates the importance of the inherent seasonal variability of influenza, which can produce counter-intuitive results, with low transmission seasons being easier to control by vaccination but resulting in fewer benefits.
Universal childhood influenza vaccination is likely to be cost-effective if a substantial herd protection effect can be achieved by the program. However, it is important that decision makers understand the role of seasonal variability and the impact of alternative methodological choices in economic evaluations of influenza vaccination.
KeywordsInfluenza Influenza Vaccination Methodological Choice General Practitioner Visit Universal Vaccination
This research was supported by a National Health and Medical Research Council (NHMRC) grant (630779). ATN holds an NHMRC Training Fellowship (630724—Australian Based Public Health Fellowship). ATN, JGW and PB are members of a Centre for Research Excellence (CRE) funded by the NHRMC (APP1031963).
Conflict of interest
ATN and JGW have in the past received research funding from a manufacturer of influenza vaccine for other previous projects.
Contribution of Authors
ATN initiated and led the project, methodological and parameterisation decisions, designed the structure of the economic aspects of the model, reviewed the literature and drafted the manuscript. JPD and PC reviewed the literature, assisted with parameterisation, helped to develop and edit the model, performed analysis, prepared figures and tables, and edited the manuscript. JW and PB were involved in model design and parameterisation decisions, and reviewed and modified the manuscript. JW also implemented and designed technical aspects of the dynamic model including calibration methods and averaging of ICER values. All authors approved the final manuscript. ATN acts as the guarantor for the project.
- 1.Joint Committee on Vaccination and Immunisation (JCVI). Minutes of the meeting held on 13 April 2012. http://transparency.dh.gov.uk/2012/05/25/jcvi-meeting-april-2012/. Accessed 6 July 2012.
- 7.Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010;(2):CD004876.Google Scholar
- 25.Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.Google Scholar
- 26.Commonwealth Department of Health and Ageing. 2006 Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) version 4.1. Canberra: Commonwealth Department of Health and Ageing; 2006.Google Scholar
- 28.Australian Bureau of Statistics. Population by age and sex, Australian states and territories (ABS catalogue number: 3201.0). Canberra: Australian Bureau of Statistics; 2010.Google Scholar
- 31.Australian Institute of Health and Welfare. 2009 Adult vaccination survey: summary results (AIHW catalogue number: PHE 135). Canberra: Australian Institute of Health and Welfare; 2010.Google Scholar
- 32.Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010;7(CD001269).Google Scholar
- 41.Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell. 2007;31(Suppl):S1–152.Google Scholar
- 42.Amaproducts.com.au. http://www.amaproducts.com.au/FLUVAC_form.pdf. Accessed 6 July 2012.
- 43.Municipal association of Victoria. Cost of Victorian local government immunisation services. Melbourne: Municipal Association of Victoria; 2004.Google Scholar
- 44.Australian Government Department of Health and Ageing. Medicare benefits scheme book. Canberra: Commonwealth of Australia; 2010.Google Scholar
- 45.Australian Government Department of Health and Aging. Medicare statistics—September quarter 2010, average patient contribution per service—out of hospital services only; 2010.Google Scholar
- 46.Chemistwarehouse.com.au. http://www.chemistwarehouse.com.au/product.asp?id=58821&pname=Influvac+0.5ml+. Accessed 6 July 2012.
- 47.Australian Bureau of Statistics. Employee earnings, benefits and trade union membership, Australia, August 2010 (ABS catalogue number 6310.0). Canberra: Australian Bureau of Statistics; 2010.Google Scholar
- 49.Australian Bureau of Statistics. Australian labour market statistics (ABS catalogue number: 6105.0). October 2010 ed. Canberra: Australian Bureau of Statistics; 2010.Google Scholar
- 50.AIHW GP Statistics and Classification Unit. SAND abstract No 9 from the BEACH program: Influenza and absenteeism. 2000.Google Scholar
- 52.Australian Refined Diagnosis Related Group (AR-DRG) (version 5.1) data recorded for each public patient hospitalised under the ICD categories for pneumonia and influenza.Google Scholar
- 54.Australian Bureau of Statistics. Life tables, Australia, 2007–2009 (ABS catalogue number: 3302.0.55.001): Commonwealth of Australia; 2010.Google Scholar